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Introduction
Acute undifferentiated febrile illness refers to a sudden onset of 
high fever without localized organ-specific clinical features1. 
Although the majority of patients recover over a few days, some 
can develop severe illnesses, resulting in high morbidity and 
even death in many parts of the world. Among the many causes 
of febrile illness, some of the most important across Asia are 
mosquito-borne viruses such as dengue virus1–6. In addition, 
novel agents associated with acute febrile illness continue to be 
discovered7–9.
Current molecular diagnostic techniques, such as polymerase 
chain reaction, are pathogen-specific and therefore pose limita-
tions, as they may fail to detect co-infections and novel agents 
not commonly associated with the disease syndrome10. The 
unbiased metagenomic sequencing of clinical material from 
patients with acute fever can overcome these limitations3,11.
Mosquito-borne viruses of the family Flaviviridae, which 
include dengue virus and Japanese encephalitis virus (JEV) are 
known to co-circulate in India and other parts of Asia12. Dengue 
viruses are a major cause of acute febrile illness in Asia, with 
recurrent outbreaks having occurred13. JEV, on the other hand, 
is better known as a cause of acute encephalitis14. Although 
JEV has been noted as an agent that causes acute fever in 
Southeast Asia, it is not routinely tested as a cause of fevers 
in India5,6. There are four distinct serotypes of dengue viruses 
(DENV1–DENV4), with their small RNA genomes (approxi-
mately 10.8 kbp) making them amenable for characterization 
by deep sequencing of infected mosquitoes or clinical mate-
rial from infected individuals15. Sequencing dengue genomes 
is important for tracking virus evolution, given that they fre-
quently mutate15,16. Outbreaks of severe dengue disease associ-
ated with serotype switches or the introduction of a novel strain 
into the population have been reported from several different 
countries, including Sri Lanka, Pakistan and Singapore17–22. Recent 
analysis suggests an influenza-virus-like pattern for dengue 
virus evolution, where strain-specific differences underlie anti-
body neutralization23. Pre-existing antibodies to circulating 
dengue strains can therefore contribute to disease severity by 
inadequate neutralization of the virus or by antibody-mediated 
enhancement, which facilitates virus infection24–28. This is sup-
ported by in vitro studies, which found that changes to the enve-
lope (E) protein of DENV3 were sufficient to alter antibody 
binding26. Multiple dengue vaccines are currently in various 
stages of development, and a tetravalent vaccine (CYD-TDV; 
Dengvaxia®, Sanofi Pasteur) has been approved for use in 
several countries29,30. This vaccine has been shown to induce the 
expression of broadly neutralizing antibodies to multiple strains 
and all serotypes of dengue viruses31. The results of a phase III 
trial of this vaccine suggest that both the immune state (with 
respect to dengue viruses) and circulating viruses may influence 
vaccine effectiveness29. This underscores the need to char-
acterize both the sequence evolution and antibody response 
of circulating dengue strains.
Here we used an unbiased sequencing/metagenomic approach, 
in order to determine both the identity and sequences of 
viruses associated with febrile illness. In particular, based 
on previous studies of sequencing data from the serum of 
febrile individuals, we expected that medium-depth sequenc-
ing (about 10–20 million sequence reads per sample) was 
necessary and sufficient to provide complete sequences of 
small viral genomes from clinical material2,9. To test this, we 
sequenced RNA extracted from the serum of four individuals 
and the plasma of another presenting with febrile illness at 
a tertiary care hospital in Bangalore, India and one healthy 
control from the same hospital, during the dengue season of 
2014. We recovered the complete coding sequence of DENV3 
clustering into a recent genotype III clade.
Results
We sequenced RNA extracted from the serum of four patients 
hospitalized with severe febrile illness and from one plasma 
sample from a patient hospitalized with prolonged febrile 
illness (Table 1). We included serum from a healthy individ-
ual and water as controls. Approximately 10×106 sequence 
reads were recovered from each sample, with the water control 
yielding a lower number of reads (Figure 1A).
A BLAST32 similarity search, mapping all sequenced reads to 
a database of NCBI reference viral sequences (Table 1), iden-
tified 19,120 DENV3 sequence reads and 14 JEV sequence 
reads in sample F2, and 12 JEV sequence reads in sample F5. 
A single DENV3 read was detected in sample F3. No animal 
viruses were confirmed by BLAST in the controls or in 
other samples (Table 1 and Figure 1B).
On the basis of World Health Organization guidelines for 
the classification of dengue cases33, F2 was classified as a 
case of severe dengue, as the presenting symptoms included 
respiratory distress (bilateral pleural effusions in chest X-ray) 
hypotension and elevated liver enzymes (Table 1).
The serum sample from this individual was positive for both 
the non-structural protein 1 antigen and dengue IgM, and we 
were able to obtain a complete DENV3 genome sequence 
from this sample. Genomes were assembled both by de novo 
(87.05% coverage) and mapping-based (99% coverage) assembly 
(Table 2 and Table 3, Supplementary File 1) and found to be 
identical (Supplementary File 2). Mapping revealed good 
coverage across the genome, with an average depth of 231.45 
(Figure 1, Table 2). The genome is missing 76 bp at the 
5’-UTR and 28 bp at the 3’-UTR compared to the NCBI 
RefSeq (NC_001475.2) DENV3 genome.
The mapping-based assembly was used for phylogenetic analysis 
and submitted to GenBank, with accession number KX855927. 
            Amendments from Version 1
Revisions have been made to the main manuscript and to  
Figure 3 based on comments from the reviewers. Modifications 
have been made in – i) Page 7, discussion, paragraph 1  
ii) page 3 – introduction, paragraph 3 iii) in the legend and results 
section for Figure 3.
See referee reports
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Figure  1. Dengue virus  type 3  (DENV3)  and Japanese encephalitis  virus  sequences  identified  from  febrile  serum.  (a) Number of 
sequence reads generated per sample. (b) Bar graph showing number of reads that aligned to a particular virus as a fraction of the total 
number of reads (y-axis, log scale) from that sample (x-axis) using the SNAP alignment. (c) Alignment of sequences mapping only to DENV3 
by nucleotide BLAST. Each rectangle shows sequencing reads (blue lines), their alignment to the genome (x-axis) and their blast bit-score 
(y-axis). Numbers below the title represents number of reads that mapped to the title. (d) Percentage identity of KX855927 with all four dengue 
viruses and the closest Indian strain.
Table 2. Assembly characteristics for mapping based assembly. The quality, coverage and percentage 
nucleotide identity of the assembled DENV3 genome using different back bones and sequences for mapping 
using MIRA assembler are shown. 
Criteria  Backbone av.qual #-reads mx.cov. av.cov GC% CnNoCov
All Reads from F2 against all  
4 Refseq of dengue viruses
DENV3 41 2009 96 26.27 46.67 145
DENV1 30 2 3 1.01 46.67 10587
DENV2 30 1 1 1 45.82 10723
DENV4 30 1 1 1 47.12 10649
“virus reads” from F2 against all 
4 Refseq of dengue viruses
DENV3 42 18180 788 231.53 46.66 104
DENV1 30 3 4 1.02 46.67 10587
DENV2 30 1 1 1 45.82 10723
DENV4 30 1 1 1 47.12 10649
“virus reads” from F2 against 
DENV3 and an Indian strain
DENV3 (RefSeq) 42 18178 793 231.51 46.66 104
AY770511.2 43 18696 792 236.58 46.65 104
Table shows the quality, coverage and percentage nucleotide identity of the assembled DENV3 genome using different back 
bones and sequences for mapping using MIRA assembler. Backbone, reference genome used for assembly; av.qual, average 
quality of assembly; mx.cov, maximum coverage of assembled genome by reads; av.cov, average coverage of assembled 
genome by reads; No cov, number of nucleotides of reference not covered in assembly; DENV3, dengue virus type 3.
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The degree of nucleotide identity between this strain and 
the reference DENV3 genome (NC_001475.2) was 96.32%, 
and with the closest DENV3 strain from India, 98.75%.
Phylogenetic analysis was carried out with BEAST2 using the 
coding sequence of KX855927 and 79 sequences selected as 
being similar to KX855927, using the BLAST search against 
dengue genomes in the Virus Pathogen Database and Analysis 
Resource34 (Supplementary File 3). The strain clusters with 
recent DENV3 sequences from India, China and Singapore 
(Figure 2). This clade split from other DENV3 and other 
DENV3 genotype III strains around 15 years ago. The branch 
length of KX855927 is longer than most others in the tree, with 
an estimated divergence time of 13.86 years (with the 95% 
highest posterior densities between 12.94 and 14.83 years) 
from the closest Indian strain (Figure 2). A maximum 
likelihood tree showed the same topology as the consensus 
tree from BEAST, although many clades had low bootstrap 
support (Supplementary File 4).
Both synonymous and non-synonymous substitutions were pre-
dicted throughout the genome, as compared to the DENV3 
reference sequence (Supplementary File 5). We aligned the 
E protein of all the complete genomes from Indian strains 
against the parent strain used to derive the tetravalent dengue 
vaccine (CYD-TDV; Dengvaxia®, Sanofi Pasteur) (Figure 3). 
Multiple amino acid substitutions were predicted throughout 
the envelope protein and two additional stop codons (at amino 
Figure 2. The sequenced strain KX855927 (2014) belongs to a recent Asian clade within genotype III. Figure shows the BEAST maximum 
clade credibility tree of the top 79 BLAST matches to KX855927 The Indo–China–Singapore strain to which KX855927 (2014) is shown in red. 
All strains are represented by their GenBank IDs and coloured by country. For ease of visualization, a clade containing viruses from the USA, 
Venezuela and Puerto Rico in Clade I has been collapsed (pyramids colored by country). The x-axis represents time in years.
Table 3. Assembly characteristics for de novo assembly. The assembly characteristics by de novo 










87.046 3127 9403 100.00% Refseq DENV3
DENV3, dengue virus type 3.
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Figure  3.  Shared  amino  acid  substitutions  in  the  envelope  protein  of  Indian  DENV3  strains  differ  from  PaH881/8.  (a) Multiple 
sequence alignment of region coding for the envelope (E) protein of dengue virus 3 from India were aligned to gi|13310784|gb|AF349
753.1| DENV3 strain PaH881/88 polyprotein precursor, translated E genes. Suffix represent the year of sampling. Predicted amino acid 
changes compared to PaH881/88 are shown in colour. Position of substitutions present in the sequenced KX855927 strain are shown in blue. 
(b) i) Cartoon structure of E protein KX855927 (2014)- dimer, homology modeled in SWISS-PROT with the domains shaded green (EDI), pink 
(EDII) and yellow (EDIII), labeled in red. ii) Cartoon structure of E protein KX855927 (2014)- dimer, homology modeled in SWISS-PROT showing 
the amino acid substitutions in KX855927 (2014) compared to the PaH881/8 in one of the dimers. In both cartoons, predicted substitutions 
are shown in blue (side-chains colored). Amino acid substitutions labelled in violet (violet box) are positions known to influence mouse 
monoclonal antibody binding. Positions in red (red box) are among 32 positions in the E protein predicted to be important for antigenicity.
acid positions 58 and 168) were observed in the DENV3 
KX855927. Most of the amino acid substitutions were shared 
among all the Indian strains, while a E361D substitution was 
unique to the DENV3 strain reported here (Figure 3A). Of the 
substitutions, 9 out of 11 were mapped onto the surface of the 
E protein. Of these, six are in key antigenic sites, with three 
sites known to influence antibody binding (Figure 3B).
The sequencing reads mapping to JEV from Sample F2 and 
F5 were assembled into contigs and used to check for potential 
alignment to other genomes in the NCBI nucleotide sequence 
database. A BLAST search revealed that the JEV sequences 
we identified were specific to JEV (100% identity, 100% cov-
erage of read) (Supplementary File 6). The sequences were 
found to match non-structural protein 5 of JEV. A specific 
search against the dengue database for the contigs from the sam-
ple containing DENV3 sequences showed no similarity for 
contig 1 and some similarity to a dengue virus 2 sequence for 
contig 2 (83% identity, 97% coverage; Supplementary File 6).
The single DENV3 sequencing read found in sample F3 
was identical to a sequencing read occurring with high fre-
quency in sample F2. Therefore, we did not carry out any 
further analysis with this sequence read as we suspect it to be a 
contamination.
Discussion
Here we sequenced a complete dengue genome from a clinical 
case of severe dengue fever, without the need to culture the virus, 
and in an unbiased manner. We believe that, in the future, the 
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sequence-based -enrichment of viral sequences using conserved 
sequences, will enable the recovery of complete genomes from rou-
tine clinical samples even with by lower-depth sequencing35.
We identified a low number of reads mapping specifically to 
JEV. JEV is known to cause fevers5,6,36. Further systematic anal-
ysis using a combination of polymerase chain reaction and 
IgM testing is required to ascertain how much JEV contrib-
utes to the acute fever burden in India. The low number of JEV 
reads obtained in both samples in which reads mapping to 
JEV were found suggests there was not much active viral 
replication occurring. There are previous reports of the detec-
tion of JEV sequences many months after infection37. The 
sequences we found could therefore be remnants of a previous 
infection or may be the result of an infection from a mosquito 
bite that was checked by the immune system. The low number 
of reads in these cases mapped to the same gene (non- 
structural protein 5) (Supplementary File 6). This could reflect 
the higher stability of some parts of the JEV RNA genome.
The results of metagenomic sequencing, however, do need 
to be interpreted with caution owing to issues related to 
contamination10,11. Contamination can occur in every step of the 
procedure, starting from sample collection, processing, sequenc-
ing and, when multiple indexed samples are sequenced 
together, de-multiplexing (the process in which reads get 
assigned to a sample). This needs to be taken into consideration, 
particularly when the number of sequences supporting the 
presence of a pathogen are low, when there is incomplete 
genome information, or when the same sequence is present in 
all the samples, including the controls. We have tried to miti-
gate this partially by the use of controls—serum from a healthy 
individual collected at the same time and place and a water 
sample processed in the same way as the clinical samples. 
However, we believe that independent methods are required to 
confirm novel/unexpected findings by this method.
DENV3 has been shown to be re-emerging in India, and has 
been responsible for severe outbreaks in other geographic 
regions, including in South America and Cuba27,38,39. The 
full-length DENV3 (KX855927) we describe here clusters into 
a clade containing DENV3 viruses from India and is related 
to an Indo–China–Singapore clade. We observed a longer 
branch length for this particular strain, which could be the result 
of incomplete sampling of this clade or could indicate that this 
lineage is showing accelerated rates of molecular evolution40. 
This can be resolved in future studies by the addition of more 
sequence information, as more full-length dengue sequences 
from India become available in the databases.
While both synonymous and non-synonymous changes were 
observed throughout the DENV3 (KX855927) genome com-
pared to the DENV3 reference sequence (NC_001475.2), 
the changes in the antigenic E protein are of particular inter-
est. Neutralizing antibodies have been described against the 
envelope protein that target particular epitopes26,41. Critical 
amino acid residues that change antibody binding have also 
been described by others26. The results from our phylogenetic 
analyses are consistent with previous work tracing the emer-
gence of new clade of DENV3 genotype III strains in India39. 
The ability of a dengue vaccine to elicit neutralizing antibodies 
against locally circulating DENV3 strains therefore needs to 
be evaluated in this light.
Methods
Description of samples
In total, samples from five patients (two diagnosed with dengue 
fever (serum; F1 and F2), two with Rickettsial fever (serum; 
F3 and F5) and one with unknown fever (plasma; F4) present-
ing with febrile illness, and one healthy control (serum; C1) at 
St. John’s Medical College and Hospital (SJMCH), Bangalore, 
were assessed in this study. Table 1 provides clinical charac-
terization, treatment and outcomes of patients. The study was 
done after obtaining approval from the Institutional Ethics 
Committee of SJMCH, Bangalore, India (IEC Study Ref. No. 
5/2016). A waiver of consent was sought and obtained for the 
analysis as it was done on samples remaining after routine diag-
nostic testing, which were de-linked from the identity of the 
patients. We have been granted a waiver of consent by the 
Institutional Ethics Committee of St. John’s Medical College 
and Hospital, which does not permit the use of the generated 
data for human genetic studies.
Isolation of RNA
RNA was extracted using the Qiagen All-Prep kit, using 
300–500 µl of serum/plasma and lysed using 1 ml of lysis buffer. 
The remaining protocol was performed as recommended by the 
manufacturer. Eluted RNA was concentrated and used for 
sequencing reactions.
Sequencing
Sequencing libraries were prepared using the Ion Proton 
library preparation protocol. Indexing was performed using the 
IonXpress RNA Seq Barcode kit (Thermo Fisher Scientific, 
Inc.). Samples F1–4 and C1 were run on the same chip; sample 
F5 was run on a separate chip. Libraries were pooled to give 
equimolar concentrations of 10 pM. This was used in template-
preparation steps and RNA sequencing was performed using 
the Ion PI sequencing kit on the Ion Proton platform using the 
Ion PI™ ChipV2 and Ion PI™ Sequencing Kit V3 (Thermo 
Fisher Scientific, Inc.).
Analysis of sequences
We aligned the sequencing reads to a database of all known 
viruses using the SNAP alignment tool (snap-1.0beta.16-linux)42. 
All hits were verified using nucleotide BLAST sequence 
search and visualized using tools from the Dark Matter 
project. Reads aligning to the human genome, human mRNA, 
rRNA large subunit and rRNA small subunit from the SILVA 
database were removed43. The aligned sequences were used as the 
input for assembly. De novo assembly was performed using 
the SPAdes (v3.10.1) tool44. Quality assessment of the assem-
bly was performed using the QUAST tool45. MIRA 4.0.2 
was used for mapping based assembly, with the GenBank 
sequence NC_001475.2 for DENV3 as the backbone for assem-
bly and NC_001437 as the backbone for JEV46. Contigs were 
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subjected to nucleotide BLAST using the online BLAST 
tool. The mapping based assembly of DENV3 obtained using 
MIRA was manually checked for regions with low confidence 
using Gap5 (staden-2.0.0b11-2016-linux-x86_64)47. Fewer than 
30 nucleotides were found to have low confidence, of which 
22 were in the 3’-UTR end region. The files from the MIRA 
assembly, together with the contributing reads, are provided 
as Supplementary File 1. This sequence was submitted 
to GenBank with the accession number KX855927.
Phylogenetic analysis
Phylogenetic analysis was performed with BLAST search hits 
to KX855927 in the VipR dengue virus database34. Only the 
coding sequence was used for the analyses. The alignment 
was visualized using AliView software (v1.18)48. Nucleotide 
distances of KX855927 from other dengue viruses, using the 
reference sequence and the closest BLAST hit from India, were 
estimated using the MUSCLE alignment tool to create a 
percentage identity matrix49. The Generalized Time Revers-
ible Model, namely GTR+I+G, GTR+I+G, GTR+G, were 
found to be the best evolutionary models for codon positions 1, 
2, and 3, respectively, using PartitionFinder (v2.1.1)50, where 
I represents invariant and G represents gamma, a shape param-
eter for the model. A previously estimated rate of substi-
tution for DENV3 =7.48×10−4 subs/site/year (4.47×10−4; 
10.72×10−4) was used to set a strict molecular clock51. The input 
XML file to BEAST (v2.4.6)52 is provided in Supplementary 
File 3. Tracer (v1.6) was used to confirm sufficient sampling 
(effective sample size > 200 for all parameters). TreeAnnotator 
(v2.4.6) was used to generate the maximum clade cred-
ibility tree, where the node heights represent median height. 
Posterior probabilities for both the split of Clade I and II and 
the clade containing KX855927 were >95%. The tree was 
visualized using FigTree (v1.4.3). The Maximum Likelihood 
tree was generated using thorough search and 1000 bootstraps 
in RaXML (RAxML -NG v0.4.1 BETA) (Supplementary File 4)53.
Analysis of E protein
E protein alignments for the DENV3 complete genomes from 
India were performed in AliView and amino acid differences 
were highlighted compared to PaH881/8 (AF349753) the par-
ent strain used in the development of Dengvaxia (CYD-TDV; a 
tetravalent, live attenuated, chimeric dengue vaccine with a 
yellow fever 17D backbone). Homology modeling was performed 
for the E protein of KX855927 using SWISS-MODELSWISS- 
MODEL and the best model was chosen for showing the 
substitutions. The protein surfaces, as visualized using PyMOL 
(version 1.8; PyMOL Molecular Graphics System, Schrödinger, 
LLC), are shown in light brown; the amino acids found to be 
different in the KX855927 strain are colored by the CHNOS 
elements. The datasets supporting the conclusions of this article 
are included within the article and in Supplementary File 1– 
Supplementary File 6.
An earlier version of this work can be found on bioRxiv 
(https://doi.org/10.1101/204503).
Data availability
The raw files from sequencing are not provided in their entirety 
as these are metagenomic datasets that contain identifying host 
information. Therefore we have used only sequences not align-
ing to the human genome for our research. This data has been 
uploaded in fastq format on OSF (see below). As our experi-
ments were designed to identify pathogens, we do expect 
the accompanying human data to be free from biases involv-
ing sampling, storage and handling. However, under the 
conditions that the samples remain de-identified, and the work 
is not directly on human genetics, approval for data sharing 
of the complete data from the RNA sequencing experiment, 
which includes any human sequences, can be sought with the 
Institutional Ethics Committee, St. John’s Medical College 
and Hospital, Bangalore. A request for use of this data for a 
research proposal must be submitted to the ethics committee 
via the lead author (soniamarydias@hotmail.com).
Fastq files have been made available from OSF, http://doi.
org/10.17605/OSF.IO/RMQDF54.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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Supplementary material
Supplementary File 1: Dengue virus type 3 assembly with contributing reads. Consensus sequence and reads contributing to the 
assembly, it contains regions/bases flagged by MIRA including 30 base positions which have low confidence. The file format (.maf) can be 
converted to compatible file formats for viewing with Gap5, Consed and other genome editors.
Click here to access the data.
Supplementary File 2: Percentage identity of dengue virus type 3 sequence assembled by different methods. Table shows the per-
centage similarity between the de novo and mapping assemblies compared to NCBI reference sequences of dengue virus types 1-4 and the 
closest Indian strain.
Click here to access the data.
Supplementary File 3: Template for BEAST. The input file used for phylogenetic analysis using the BEAST program.
Click here to access the data.
Supplementary File 4: Maximum Likelihood Tree from RaxML. Figure shows the maximum likelihood trees with bootstrap values, 
GenBank IDs and year of sequencing are shown on the tips. The data is coloured by country and some of the clades have been collapsed 
for ease of viewing.
Click here to access the data.
Supplementary File 5: Single nucleotide polymorphisms in KX855927 with respect to NC_001475. Description of the single nucle-
otide polymorphisms in KX855927 with respect to NC_001475, as detected by the MIRA assembly program.
Click here to access the data.
Supplementary File 6: BLAST results of Japanese encephalitis virus contigs from sample F2 and F5. Contains the Top 5 nucleotide 
BLAST lists for the Japanese encephalitis virus contigs assembled from samples F2 and F5, against the nucleotide database, flavivirus 
database and dengue virus database.
Click here to access the data.
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1. New Generation sequencing approaches are attractive options to identify viral quasispecies in
patients. In the present article, the authors have presented a common consensus final sequence of
DENV-3 and compared it with reference sequence and the closely related GWL-25 genome. Did
the authors had a chance  to look at the raw read clusters, and identify possible variations that
could represent quasi species by looking at sites/ sequence regions showing consistent
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 the RefSeq DENV3 strain are included in Supplementary File 5. 
2. Considering that DENV virus protein translation starts as a polyprotein formation from a single
ORF, identifying two internal stop codons at positions 58 & 168 seems to be curious. Have the
authors done a manual verification of the corresponding raw read alignments? What could be the





3.The authors have identified two missing regions-one each in the 5' and 3' UTR. Are they internal
gaps or terminal truncation in the sequence? Could this be a failure to sequence these regions by
the technique or is it possible that the DENV-3 strain itself is lacking these regions? Since the




4.In the result section, the unique substitution is mentioned as D361E, where as in the fig.3A it is








5. In Fig.3b(ii), the authors have highlighted the amino acid residues that are important in antibody
binding and antigenicity. But how many of these changes are functionally important, based on the
chemical nature of the amino acid substitutions observed? Also, the authors should indicate the
wild type as well as the mutant amino acids along with the position number in the figure.
The figure and accompanying legend have been modified. 
6.Was there any specific reason in using plasma sample from one patient and serum from
others? It would be good to indicate, if available, the duration of fever in F1, and treatment and
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